88 results
S-3ASR
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
for the fiscal year ended December 31, 2023, filed with the SEC on March 21, 2024, for more information regarding our business and corporate strategy … capabilities and strategy;
our plans to collaborate, or statements regarding our current collaborations with BioNTech and others, including our
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
,” “ongoing,” “objective,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “strategy,” “target,” “will” and “would” or the negative of these terms … Hamas and Israel, and global geopolitical tension;
our commercialization, marketing and manufacturing capabilities and strategy;
our plans
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
of the antibody; (e) been mutated using an affinity maturation strategy designed to modify the affinity of either the variable regions … Member and Chief Strategy Officer By: /s/ Sierk Poetting Name: Sierk Poetting Title: Management Board Member and Chief Operating Officer AUTOLUS LIMITED
8-K/A
EX-99.1
AUTL
Autolus Therapeutics plc
15 Mar 24
Results of Operations and Financial Condition
4:21pm
analysis or would it be the pivotal cohort? Also, since you commented on your bridging therapy strategy, I was wondering, does that have any implications
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
with University College London Expand obe-cel opportunity in B cell malignancies, autoimmune diseases & life cycle strategy – SLE – B-NHL indications – Bi-specific … collaborations Pipeline expansion strategy Scalable manufacturing and in-house facility Cash $240M (Q4 2023) and gross proceeds of $600m from financing
8-K
EX-99.1
4b8gghi xmqgzdeb
13 Feb 24
Regulation FD Disclosure
4:06pm
424B5
tgnr5be
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-10.3
sb5pg0ma
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-10.2
jyi u33jvuppj
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-10.1
r7igu
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
sjsvbzbp
7 Feb 24
Automatic shelf registration
10:00pm
8-K
EX-99.1
jql3byy2lcdktyq0
22 Dec 23
Departure of Directors or Certain Officers
8:24am
8-K
EX-99.2
wolkejtyny
11 Dec 23
Regulation FD Disclosure
8:31am
10-Q
19qkuql
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.3
9tyj3 6ty03
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.1
5a7nxjgs cgi2para
21 Jul 23
Current report (foreign)
4:07pm
6-K/A
EX-99.2
dvh h1fhbf2m
6 Jul 23
Current report (foreign) (amended)
5:38pm
6-K
EX-99.2
1zoisno8iz
6 Jun 23
Current report (foreign)
8:18am
6-K
EX-99.3
2jx5hka2 rrufwpu
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
424B5
e7qpb1fj 4760u7xb
9 Dec 22
Prospectus supplement for primary offering
5:40pm